Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $91.0 million.

  • Avidity Biosciences' Other Non-Current Assets rose 3157.32% to $91.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.0 million, marking a year-over-year increase of 3157.32%. This contributed to the annual value of $2.8 million for FY2024, which is 828.57% up from last year.
  • Avidity Biosciences' Other Non-Current Assets amounted to $91.0 million in Q3 2025, which was up 0.26% from $90.8 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Other Non-Current Assets ranged from a high of $91.0 million in Q3 2025 and a low of $301,000 during Q4 2023.
  • Over the past 3 years, Avidity Biosciences' median Other Non-Current Assets value was $2.8 million (recorded in 2025), while the average stood at $17.7 million.
  • In the last 5 years, Avidity Biosciences' Other Non-Current Assets slumped by 49.67% in 2023 and then surged by 3,157.32% in 2025.
  • Avidity Biosciences' Other Non-Current Assets (Quarterly) stood at $599,000 in 2021, then fell by 0.17% to $598,000 in 2022, then tumbled by 49.67% to $301,000 in 2023, then soared by 828.57% to $2.8 million in 2024, then surged by 3,157.32% to $91.0 million in 2025.
  • Its last three reported values are $91.0 million in Q3 2025, $90.8 million for Q2 2025, and $2.8 million during Q1 2025.